Immune complex-mediated neutrophil activation in patients with polymyalgia rheumatica


 
 
 Neutrophils are important in host defense. However, neutrophils are also linked to inflammation and organ damage. The purpose of this study was to assess whether markers of neutrophil activation are increased in polymyalgia rheumatica.
 
 
 
 Levels of immune complexes (IC), calprotectin, and neutrophil extracellular traps (NETs) were measured in plasma of healthy individuals (n = 30) and patients with PMR (n = 60), at flare and upon treatment with glucocorticoids using ELISA. Plasma-mediated neutrophil activation was assessed in presence of an FcγRIIA inhibitory antibody (IV.3).
 
 
 
 Plasma levels of calprotectin and NETs were elevated in PMR (p < 0.001). Mechanistically, neutrophil activation was driven by ICs, present in plasma, able to up-regulate neutrophil activation markers CD66b and CD11b (p < 0.0001) in an FcγRIIA-dependent manner (p < 0.01). Of note, circulating levels of IC correlated with plasma induced CD66b and CD11b (r = 0.51, p = 0.004, and r = 0.46, p = 0.01 respectively) and decreased after glucocorticoid therapy.
 In contrast to NETs, calprotectin significantly decreased after glucocorticoid therapy (p < 0.001) and was higher in PMR without overlapping giant cell arteritis (GCA) compared to patients with overlapping disease (p = 0.014). Interestingly, musculoskeletal involvement was associated with elevated levels of calprotectin before initiation of glucocorticoid therapy (p = 0.036).
 
 
 
 Neutrophil activation, including NET formation, is increased in PMR, through IC-mediated engagement of FcγRIIA. Clinically, neutrophil activation is associated with musculoskeletal involvement, with calprotectin, but not NETs, being a biomarker of treatment response in PMR patients. In all, IC-mediated neutrophil activation is a central process in PMR pathogenesis identifying potential novel therapeutic targets (FcγRIIA), as well as soluble markers for disease monitoring (calprotectin).
